Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
Week’s Option Activity (1/13 ~ 1/28)
The following stocks had notable activity in their options during the past week(s): $XOMA (1/13): 2,550 JUN risk reversals were purchased (stock at $8.32) for 0.40 or $102,000. 2,550 JUN 15.0 strike Calls were purchased for 0.88 and 2,550 JUN 5.0 strike Puts were sold against for 0.48. Buyer expects substantial upside movement and makes […]
Catalyst Watch – Vol. 2, Edition 2 (1/24/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CHTP: […]
Catalyst Watch – Vol. 2, Edition 1 (1/14/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: KERX: […]
Week’s Option Activity (12/27 ~ 1/9)
The following stocks had notable activity in their options during the past week(s): $GERN (12/27): 663 JUN 5.0 strike Calls (stock at $5.10) were purchased for 1.40 or total cost of $92,820. Buyer makes money if stock trades above $6.40 by June expiration. $CHTP (12/31): 5,500 JAN 4.0 strike Puts (stock at $4.40) were purchased […]
Catalyst Watch – Vol. 1, Edition 11 (12/31/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: […]
Catalyst Watch – Vol. 1, Edition 10 (12/13/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: Catalyst Watch List – Update: KERX: […]
Catalyst Watch – Vol. 1, Edition 9 (12/4/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: Catalyst Watch List – Update: MACK: […]
Catalyst Watch – Vol. 1, Edition 8 (11/20/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision. Please read the site Disclaimer: Catalyst Watch List – Update: MACK: No change to strategy (see […]
Catalyst Watch – Vol. 1, Edition 7 (11/12/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: Catalyst Watch List – Update: VNDA: The stock is up 80% on better than expected briefing […]
Week’s Option Activity (10/31~11/4)
The following stocks had notable activity in their options during the past week(s): $VNDA (10/31): Lots of activity – we will stick to the bigger trades. 1,000 NOV 4.0 strike Puts were sold (stock at $6.74) to buy 1,000 NOV 11.0 strike Calls for a net debit of 0.65 or $65,000 – buyer makes money […]
Catalyst Watch – Vol. 1, Edition 6 (10/30/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: Catalyst Watch List – Update: VNDA: The stock has sold off substantially, from $13 to $7, […]
Catalyst Watch – Vol. 1, Edition 5 (10/22/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: VNDA: No change in strategy (See Vol. 1, Edition 2). […]
Catalyst Watch – Vol. 1, Edition 4 (10/11/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Waiting for briefing docs… More to follow on this […]
Catalyst Watch – Vol. 1, Edition 3 (10/2/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: Stock continues to climb (now at $6.85). No delay […]
Catalyst Watch – Vol. 1, Edition 2 (9/26/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: (1) Catalyst Watch List – Updates: AMRN: The stock is up slightly ($6.58) from our last […]
Catalyst Watch – Vol. 1, Edition 1 (9/20/13)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date of publishing (or are noted) and are subject to potential future, pre-catalyst revision: Ticker: VNDA ($13.16) Catalyst: AdCom for Tasimelteon Date/Timing: November 14, 2013 CRG View: Bearish Cash: $151.9m […]
Week’s Option Activity (6/3~6/7)
The following stocks had notable activity in their options during the past week: $AFFY (6/3): 3,000 JAN14 2.0 strike Calls were purchased (stock at $2.08) for a debit of 0.45 or $135,000. Buyer makes money if stock is greater than $2.45 by expiration. Stock was subsequently de-listed from the NASDAQ on June 6. Oops. $CHTP […]
